Gastrointestinal symptoms by Blastocystis hominis
Conditions
Interventions
Trade Name: Metronidazol
Product Name: metronidazol
Product Code: D06BX01
Pharmaceutical Form: Tablet
Trade Name: Setrin Forte
Product Name: Septrin Forte
Product Code: DB00916
Pharmaceutical Form: T
Sponsors
Hospital Universitari Mutua Terrassa
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Age > 18 years, gastrointestinal clinic symptoms of at least 1 month of duration, positive Blastocystis hominis in faeces. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 154 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 50
Exclusion criteria
Exclusion criteria: Other gastrointestinales diseases, allergy to medicines of the study, pregnancy, breastfeeding, antibiotic ingestion in the last month.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To analyze the efficacy of the paramomicin and cotrimoxazol in comparison with metronidazol in the eradication of Blastocystis hominis in simptomatic patients.;Secondary Objective: There is not a secondary objective;Primary end point(s): Confirmation of the eradication of the Blastocystis hominis by intention to treat after 4 weeks of finalized treatment, through the determination of negative faeces parasites in 3 samples.;Timepoint(s) of evaluation of this end point: 40 days | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): Clinical response and therapeutic compliance;Timepoint(s) of evaluation of this end point: Clinical response at 10 days and 40 days | — |
Countries
Spain
Contacts
Public ContactNuria Giménez-Gómez
Hospita Universitari Mutua Terrassa
Outcome results
None listed